Building access to the Regenstrief Institute is currently restricted. More on our coronavirus precautions.
See our coronavirus precautions.

STUDY DATES: 05/01/2019 – 03/31/2024

As many as 30% of older adults use a medication that increases the risk of Alzheimer’s disease and related dementias (ADRD), however no study has yet tested whether stopping anticholinergics in current users results in improved and sustained benefit on cognition.

This proposal will conduct a randomized trial to determine if a pharmacist-based, anticholinergic de-prescribing intervention improves cognition and lowers the risk of ADRD in primary care Deprescribing definition and graphicsolder adults with subjective cognitive dysfunction. Safety measures for disease severity and quality of life will complement the cognitive outcomes in the 24 month duration of the study.

Center for Aging Research

Campbell NL, Holden RJ, Boustani MA. Preventing Alzheimer’s disease by deprescribing anticholinergic medications. JAMA Intern Med 2019; 179(8):1093-1094.

Campbell NL, Solid CA, Boustani MA. Anticholinergics and dementia: the importance of patient education. Aging Today 2018;39:5.

Richardson K, Fox C, Maidment I, Steel N, Loke YK, Arthur A, Myint PK, Grossi C, Mattishent K, Bennett K, Campbell NL, Boustani M, Robinson L, Brayne C, Matthews F, Savva G. The association between up to 20 year history of anticholinergic medication use and dementia incidence varies by drug class: A nested case-control study using the Clinical Practice Research Datalink. BMJ 2018; Apr 25;361:k1315. doi: 10.1136/bmj.k1315. PMID: 29695481.

Campbell NL, Lane KA, Gao S, Boustani M, Unverzagt F. Anticholinergics increase transition
from normal cognition to mild cognitive impairment in community-dwelling older adults. Pharmacotherapy 2018 May;38(5):511-519. doi: 10.1002/phar.2106. Epub 2018 Apr 25.
PMID: 29600808. https://doi.org/10.1002/phar.2106.

Campbell NL, Perkins AJ, Bradt P, Perk S, Wielage R, Boustani M, Ng D. The association of anticholinergic burden with cognitive impairment and healthcare utilization. Pharmacotherapy 2016;36(11):1123-1131.

Campbell N, Boustani M, Lane K, Gao S, Hendrie H, Khan B, Murrell J, Unverzagt F, Hake A, Smith-Gamble V, Hall D. Use of anticholinergics and the risk of cognitive impairment in an African-American population. Neurology 2010;75:152-159.

June 24, 2019 • Expert Opinion, News
Can Deprescribing Drugs Linked to Cognitive Impairment Actually Reduce Risk of Dementia?
JAMA Internal Medicine commentary highlights opportunity to discover modifiable risk factors for dementia In a commentary published in JAMA Internal Medicine, three Regenstrief Institute  research scientists write that while they and other researchers have identified a strong and consistent link between anticholinergic drugs and cognitive impairment from observational studies, randomized clinical trials represent the only […]
Continue Reading >
June 18, 2019 • News
Regenstrief scientist explains how class of drugs may be related to dementia
Regenstrief research scientist Noll Campbell, PharmD, M.S., spoke about a common class of drugs and how it affects the brain on an Indianapolis radio show. Dr. Campbell was a guest on Caregiver Crossing, which airs every Saturday on 93.1 WIBC. Dr. Campbell addressed the topic of anticholinergics and their potential link to Alzheimer’s and dementia. […]
Continue Reading >
May 28, 2019 • Announcements, News
First study to see if de-prescribing commonly used drug class prevents or delays dementia
Regenstrief researcher receives $3.3 million NIA award for cause and effect study Regenstrief Institute research scientist Noll Campbell, PharmD, MS has received a five-year $3.3 million award from the National Institute on Aging (NIA) to conduct the first clinical trial designed to determine if stopping anticholinergic medications results in sustained improvements in cognition. Anticholinergic medications […]
Continue Reading >
Partners
NIA